ReviewPharmacoEconomics2006

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Arran T Shearer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.